Study [Ref.] | Country | miRNA-130a | miRNA-130b | Histology | TNM stage | Sample | Assay | Follow-up (months) | Cut-off | HR (95% CI) | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OS | Other | OS | Other | OS | DFS/PFS | ||||||||
Jia 2019 [44] | China | 284 |  |  |  | Gastric cancer | I–IV | Frozen tissue | qRT-PCR | 50 | Median | 2.44 (1.35,4.40) |  |
Peng 2018 [18] | China | 333 | DFS,333 |  |  | Gastric cancer | I–III | Serum | qRT-PCR | 59 | Median | 1.49 (0.99,2.26) | 1.38 (0.99,1.91) |
Liu 2018 [45] | China | 369 |  |  |  | Colorectal cancer | I–IV | Serum | qRT-PCR | 60 | Median | 2.36 (1.07,5.22) |  |
Yang 2018 [46] | China | 60 | DFS,60 |  |  | Colorectal cancer | I–IV | Frozen tissue | qRT-PCR | 70 | Median | 2.25 (1.05,4.83) |  |
Asukai 2017 [16] | Japan | 27 | DFS,27 | Â | Â | Cholangiocarcinoma | NA | Frozen tissue | qRT-PCR | 82 | Median | 2.36 (1.18,4.17) | 2.47 (1.10,5.56) |
Zhou 2017 [47] | China | 51 |  |  |  | HCC | I–III | Frozen tissue | qRT-PCR | 42 | Normal | 1.23 (0.78,1.96) |  |
Chen 2016 [11] | China | 86 | DFS,86 |  |  | Osteosarcoma | I–IV | Frozen tissue | qRT-PCR | 60 | Median | 2.14 (1.14,4.02) | 2.04 (1.22,3.40) |
Jiang 2016 [17] | China | 41 |  |  |  | Gastric cancer | I–III | Frozen tissue | qRT-PCR | 36 | Normal | 2.05 (1.03,4.08) |  |
Yuan 2016 [14] | China | 56 | Â | Â | Â | Lymphoma | NA | Frozen tissue | qRT-PCR | 50 | Median | 1.23 (0.94,1.61) | Â |
He 2014 [15] | China | 73 | DFS,73 |  |  | Cervical cancer | I–IV | Frozen tissue | qRT-PCR | 86 | Normal | 1.41 (0.30,6.63) | 1.73 (0.14,21.52) |
Li 2014 [21] | China | 102 |  |  |  | HCC | I–III | Frozen tissue | qRT-PCR | 72 | Normal | 0.45 (0.22,0.90) |  |
Wang 2012 [48] | China |  | DFS,100 |  |  | NSCLC | I–III | Frozen tissue | qRT-PCR | 96 | Normal |  | 0.21 (0.09,0.50) |
Hashimoto 2019 [49] | America (AA) |  |  | 36 |  | Prostate cancer | I–IV | Frozen tissue | qRT-PCR | 260 | Mean | 22.4 (2.27,221.3) |  |
America (EA) |  |  | 57 |  | Prostate cancer | I–IV | Frozen tissue | qRT-PCR | 250 | Mean | 1.10 (0.21,5.74) |  | |
Ulivi 2019 [50] | Italy |  |  | 83 | DFS,85 | NSCLC | I–IIIA | Serum | qRT-PCR | 160 | Median | 1.35 (1.08,1.69) | 1.35 (1.08,1.69) |
Hu 2018 [51] | China | Â | Â | 110 | Â | HCC | NA | Serum | qRT-PCR | 60 | Median | 6.58 (3.04,14.24) | Â |
Ecke 2017 [52] | Germany (TC) | Â | Â | 100 | Â | Bladder-cancer | NA | Frozen tissue | qRT-PCR | 156 | Median | 0.99 (0.82,1.20) | Â |
Germany (VC) | Â | Â | 56 | Â | Bladder-cancer | NA | Frozen tissue | qRT-PCR | 156 | Median | 1.02 (0.53,1.96) | Â | |
Li 2017 [22] | China | Â | Â | 85 | Â | Glioma | NA | Frozen tissue | qRT-PCR | 36 | Mean | 2.22(1.38,3.56) | Â |
Chang 2016 [23] | China (TC) |  |  | 85 | DFS,85 | HCC | I–III | Frozen tissue | qRT-PCR | 66 | Normal | 1.01 (0.38,2.72) | 2.02 (1.33,3.07) |
China (VC) |  |  | 65 | DFS,65 | HCC | I–III | Frozen tissue | qRT-PCR | 80 | Normal | 1.93 (1.30,2.87) | 1.73 (1.16,2.58) | |
Sheng 2015 [24] | China | Â | Â | 86 | Â | Glioma | NA | Frozen tissue | qRT-PCR | 36 | Median | 4.39 (1.50,12.82) | Â |
Wang 2014 [25] | China |  |  | 97 | DFS,97 | HCC | I–IV | Frozen tissue | qRT-PCR | 60 | Median | 2.52 (1.24,5.15) | 4.00 (1.52,10.54) |
Kjersem 2014 [30] | Norway | Â | Â | 150 | PFS,150 | Colorectal cancer | NA | Serum | qRT-PCR | NA | Median | 1.31 (0.96,1.79) | 1.40 (1.05,1.86) |
Colangelo 2013 [26] | Italy |  |  | 80 |  | Colorectal Cancer | I–IV | Frozen tissue | qRT-PCR | 108 | Mean | 5.99 (1.99,18.03) |  |
Zhao 2013 [31] | China |  |  | 52 |  | Pancreatic cancer | I–IV | Frozen tissue | qRT-PCR | 36 | Median | 2.84 (1.25,6.45) |  |
Nakatani 2012 [53] | Italy | Â | Â | 49 | Â | Sarcoma | NA | Frozen tissue | qRT-PCR | 217 | Median | 2.11 (1.22,3.63) | Â |